MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

SciClone Pharmaceuticals Company Profile (NASDAQ:SCLN)

Consensus Ratings for SciClone Pharmaceuticals (NASDAQ:SCLN) (?)
Ratings Breakdown: 1 Sell Rating(s), 1 Buy Rating(s)
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: N/A

Analysts' Ratings History for SciClone Pharmaceuticals (NASDAQ:SCLN)
Show:
DateFirmActionRatingPrice TargetActions
7/9/2015BWS FinancialDowngradeHold -> SellView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/29/2015MLV & Co.Initiated CoverageBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/6/2015AegisReiterated RatingPositiveView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/28/2014 forward)
Earnings History for SciClone Pharmaceuticals (NASDAQ:SCLN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/8/2016        
5/10/2016Q116$0.19$33.60 million$36.50 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/10/2016Q415$0.30$41.10 million$42.90 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/9/2015Q315$0.12$0.26$40.61 million$42.90 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/10/2015Q215$0.12$0.26$37.27 million$37.90 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/11/2015Q414$0.03$0.17$34.00 million$33.60 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/11/2015Q4$0.15$0.29$38.93 million$41.43 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/10/2014Q314$0.12$0.17$34.90 million$34.30 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/11/2014Q214$0.10$0.20$33.40 million$32.50 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/12/2014Q114$0.08$0.10$32.20 million$26.60 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/12/2014Q314$0.15$0.08$38.30 million$32.70 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/12/2013Q114$0.15$0.18$39.70 million$35.20 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/7/2013Q2 2013$0.11$0.09$33.30 million$29.81 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/1/2013Q4 2012$0.12$0.04$35.30 million$33.10 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/9/2012Q312$0.21$0.20$43.09 million$40.70 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/8/2012$0.18$0.20ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/9/2012$0.11$0.15ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for SciClone Pharmaceuticals (NASDAQ:SCLN)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividend History for SciClone Pharmaceuticals (NASDAQ:SCLN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for SciClone Pharmaceuticals (NASDAQ:SCLN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
3/28/2016Friedhelm BlobelCEOSell10,000$9.29$92,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/18/2016Friedhelm BlobelCEOSell10,000$9.09$90,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/7/2016Friedhelm BlobelCEOSell20,000$10.01$200,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/26/2016Friedhelm BlobelCEOSell10,000$9.98$99,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/4/2016Friedhelm BlobelCEOSell200$9.01$1,802.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/28/2015Friedhelm BlobelCEOSell10,000$9.17$91,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/17/2015Friedhelm BlobelCEOSell9,400$9.00$84,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/11/2015Friedhelm BlobelCEOSell600$9.00$5,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/4/2015Friedhelm BlobelCEOSell10,000$9.22$92,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/3/2015Lan XieCFOSell14,166$9.50$134,577.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/27/2015Friedhelm BlobelCEOSell10,000$9.24$92,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/10/2015Wilson Wai-Shun CheungCFOSell7,803$9.51$74,206.53View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/24/2015Friedhelm BlobelCEOSell10,000$9.68$96,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/17/2015Friedhelm BlobelCEOSell10,000$9.72$97,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/10/2015Friedhelm BlobelCEOSell10,000$9.21$92,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/6/2015Friedhelm BlobelCEOSell20,000$10.80$216,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/26/2015Friedhelm BlobelCEOSell10,000$9.29$92,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/19/2015Friedhelm BlobelCEOSell10,000$9.42$94,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/12/2015Chuncai MengVPSell3,007$9.23$27,754.61View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/12/2015Friedhelm BlobelCEOSell10,000$9.13$91,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/8/2015Hong ZhaoCEOSell10,000$9.23$92,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/5/2015Friedhelm BlobelCEOSell10,000$9.07$90,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/1/2015Richard J HawkinsDirectorSell4,570$9.27$42,363.90View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/29/2015Friedhelm BlobelCEOSell10,000$9.38$93,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/29/2015Richard J HawkinsDirectorSell10,430$9.32$97,207.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/26/2015Richard J HawkinsDirectorSell11,982$9.44$113,110.08View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/22/2015Friedhelm BlobelCEOSell10,000$9.40$94,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/18/2015Chuncai MengVPSell23,660$9.56$226,189.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/15/2015Lan XieCFOSell26,668$9.20$245,345.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/24/2015Friedhelm BlobelCEOSell10,000$9.07$90,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/10/2015Friedhelm BlobelCEOSell10,000$9.10$91,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/12/2015Wilson Wai-Shun CheungCFOSell7,803$9.07$70,773.21View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/11/2014Richard J HawkinsDirectorSell15,591$8.80$137,200.80View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/2/2014Lan XieCFOSell36,468$6.97$254,181.96View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/15/2014Nancy T ChangDirectorBuy25,040$6.00$150,240.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/16/2014Hong ZhaoCEOSell12,500$4.75$59,375.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/22/2013Min YinVPSell10,938$5.50$60,159.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/20/2013Min YinVPSell12,500$5.50$68,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/28/2013Friedhelm BlobelCEOBuy3,000$3.86$11,580.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for SciClone Pharmaceuticals (NASDAQ:SCLN)
DateHeadline
06/28/16 11:06 AMSciclone Pharmaceuticals (NASDAQ:SCLN) Short Interest Increased By 3.11% - Press Telegraph
06/27/16 03:29 PMSciClone Pharmaceuticals, Inc. – Value Analysis (NASDAQ:SCLN) : June 27, 2016 -
06/24/16 08:01 AMSciClone Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : SCLN-US : June 24, 2016 -
06/23/16 08:55 AMSciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) Stock Momentum Hits Strength - CML News
06/20/16 05:58 PMSciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) Analyst Price Targets For The Coming Week - Fiscal Standard
06/15/16 06:13 PMSciClone Pharmaceuticals Inc. (SCLN) is Trading Higher on Unusual Volume for June 13 - Equities.com
06/15/16 11:36 AMSCICLONE PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to -
06/14/16 06:00 PMSciClone Pharmaceuticals Inc. (SCLN) Jumps 5.36% on June 13 - Equities.com
06/09/16 06:48 PMSciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) Fundamental Star Rating Report - CML News
06/04/16 09:17 AMBiotech Stocks Update: Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) , SciClone Pharmaceuticals, Inc ... - Is stories
06/03/16 02:40 PMETF’s with exposure to SciClone Pharmaceuticals, Inc. : June 3, 2016 -
06/03/16 02:19 PM3 Biotech Stocks Headed for New Highs (SCLN, SUPN) -
06/03/16 09:16 AMSciClone Pharmaceuticals Inc. (SCLN) is Trading Lower on Unusual Volume for June 01 - Equities.com
06/03/16 09:16 AMSciClone Pharmaceuticals Inc. (SCLN) Hits New 52-week High During June 01 Session - Equities.com
06/02/16 06:47 PMTraders Actions to Focus: SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) , Raptor Pharmaceutical Corp. (NASDAQ ... - Street Updates - Traders Actions to Focus: SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) , Raptor Pharmaceutical Corp. (NASDAQ ...Street UpdatesOn 6/1/2016, SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) highlighted downward shift of -0.64% or -0.09 points to $14.06. The company traded a volume of 1.29 million shares over average volume of 611.5 thousand shares. Trailing twelve month period, ...and more »
06/02/16 09:24 AMAnalyst Recommended These Stocks for Investors: Unit Corporation (NYSE:UNT), SciClone Pharmaceuticals, Inc ... - Beacon Chronicle - Beacon ChronicleAnalyst Recommended These Stocks for Investors: Unit Corporation (NYSE:UNT), SciClone Pharmaceuticals, Inc ...Beacon ChronicleSciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) currently has High Price Target of $10. The Low and Mean Price Targets are $10 and $10 respectively. These price targets are a consensus analysis of 1 brokers. When having a look at Recommendation ...and more »
06/02/16 09:24 AMSciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) Change In Inventory At $1.432 Millions - RealistInvestor.com - SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) Change In Inventory At $1.432 MillionsRealistInvestor.comSciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) accounts payable was $4.495 millions for the fiscal closed 2015-12-31. For the quarter ended 2015-12-31 it was $4.495 millions. At the end of the year 2015-12-31, the deviation in accounts payable was ...
06/01/16 06:55 PMSciClone Pharmaceuticals, Inc. (SCLN) Sees 52-Week High - Finance Daily - SciClone Pharmaceuticals, Inc. (SCLN) Sees 52-Week HighFinance DailyThe stock of SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) hit a new 52 week high point reaching $14.22 in trading on Wednesday. Shares closed down 0.64% when all was said and done. Volume came in at 1,234,180 and the stock hit $13.91 at its ...What's Ahead for SciClone Pharmaceuticals, Inc. After Reaching 52-Week High?The Postall 2 news articles »
05/31/16 06:38 PMSciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) Quarterly EPS Estimate At $0.00 - Investor Newswire - SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) Quarterly EPS Estimate At $0.00Investor NewswireFirst Call stated that SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) can touch $10.00 in coming one year. For the next quarter, the per-share earnings target is $0.00 and for ongoing fiscal at $0.33. EPS target for next year is $0.68 versus the mean EPS ...and more »
05/31/16 06:38 PMSciClone Pharmaceuticals Inc. (SCLN) Jumps 7.81% on May 31 - Equities.com - SciClone Pharmaceuticals Inc. (SCLN) Jumps 7.81% on May 31Equities.comSciClone Pharmaceuticals Inc. (SCLN) was among the biggest gainers on the Russell 2000 for Tuesday May 31 as the stock popped 7.81% to $14.15, representing a gain of $1.025 per share. Some 856,607 shares traded hands on 6,542 trades, compared ...and more »
05/26/16 01:07 PMNantahala Capital Management LLC Increased Sciclone Pharmaceuticals INC (NASDAQ:SCLN) by $15.99 Million as ... - CCH Daily News - Nantahala Capital Management LLC Increased Sciclone Pharmaceuticals INC (NASDAQ:SCLN) by $15.99 Million as ...CCH Daily NewsWilmot B. Harkey increased its stake in Sciclone Pharmaceuticals Inc (NASDAQ:SCLN) by 254.12% based on its latest 2016Q1 regulatory filing with the SEC. Nantahala Capital Management Llc bought 1.45M shares as the company's stock rose 26.73% with ...and more »
05/24/16 02:36 PMETF’s with exposure to SciClone Pharmaceuticals, Inc. : May 24, 2016 -
05/23/16 01:04 PMSciClone Pharmaceuticals, Inc. :SCLN-US: Earnings Analysis: Q1, 2016 By the Numbers : May 23, 2016 -
05/10/16 01:29 PMEdited Transcript of SCLN earnings conference call or presentation 10-May-16 12:30pm GMT -
05/10/16 06:34 AMSCICLONE PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements -
05/10/16 06:07 AMQ1 2016 SciClone Pharmaceuticals Inc Earnings Release - After Market Close -
05/10/16 05:18 AMSciClone Pharmaceuticals To Report First Quarter 2016 Financial Results On May 10, 2016 - [at noodls] - FOSTER CITY, Calif., April 25, 2016 /PRNewswire/ -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that it plans to report financial results for the first quarter 2016 on Tuesday, May 10, ...
05/10/16 05:14 AMSciClone posts 1Q profit -
05/10/16 05:00 AMSciClone Reports First Quarter 2016 Financial Results - [PR Newswire] - FOSTER CITY, Calif., May 10, 2016 /PRNewswire/ -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today reported financial results for the quarter ended March 31, 2016. Revenues: In the first quarter 2016, ...
04/18/16 06:21 AMSciClone To Present At Needham Healthcare Conference On April 13, 2016 - [at noodls] - FOSTER CITY, Calif., March 30, 2016 /PRNewswire/-- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that Wilson W. Cheung, Chief Financial Officer, will present a corporate overview and business ...
04/16/16 08:00 AM'Mad Money' Lightning Round: Con Ed, Regeneron Are My Picks -
04/14/16 11:00 PMCramer: Two best stocks in a dangerous group -
03/31/16 03:59 PMHere's Why SciClone Pharmaceuticals' Shares Are Soaring 14% Today - The company is being added to the S&P 600 Index.
03/11/16 12:29 PMSCICLONE PHARMACEUTICALS INC Files SEC form 10-K, Annual Report -
03/11/16 04:01 AMSciClone posts 4Q profit -
03/10/16 10:11 PMEdited Transcript of SCLN earnings conference call or presentation 10-Mar-16 9:30pm GMT -
03/10/16 03:05 PMSciClone Reports 2015 Financial Results - [PR Newswire] - FOSTER CITY, Calif., March 10, 2016 /PRNewswire/ -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today reported financial results for the quarter and year ended December 31, 2015. Revenues: Revenues for ...
03/10/16 06:07 AMQ4 2015 SciClone Pharmaceuticals Inc Earnings Release - After Market Close -
03/08/16 01:45 PMLifeSci Capital Initiates Coverage of SciClone - [Accesswire] - Profitable Specialty Pharmaceutical Company with Steady Revenue Growth; Report Available here: http://www.lifescicapital.com/equity-research/sciclone/ NEW YORK, NY / ACCESSWIRE / March 8, 2015 / LifeSci ...
02/28/16 01:40 PMSciclone Pharmaceuticals (NASDAQ:SCLN) Shorted Shares Increased By 0.24% - Stock Caller - Sciclone Pharmaceuticals (NASDAQ:SCLN) Shorted Shares Increased By 0.24%Stock CallerThe short interest to Sciclone Pharmaceuticals's float is 7.48%. The stock increased 2.60% or $0.25 during the last trading session, hitting $9.86. About 205,650 shares traded hands. SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) has risen 0.51% since ...
02/28/16 01:40 PMSciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) Updated Price Targets - Share Trading News - SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) Updated Price TargetsShare Trading News02/28/2014 – SciClone Pharmaceuticals, Inc. was upgraded to “hold” by analysts at EVA Dimensions. SciClone Pharmaceuticals, Inc. has a 50 day moving average of 8.33 and a 200 day moving average of 8.20. The stock's market capitalization is 486.85M, ...
02/26/16 08:56 AMCommit To Purchase SciClone Pharmaceuticals At $7.50, Earn 12.2% Annualized Using Options - Investors considering a purchase of SciClone Pharmaceuticals, Inc. (SCLN) shares, but tentative about paying the going market price of $9.74/share, might benefit from considering selling puts among the alternative strategies at their disposal. One ...
02/22/16 05:00 AMSciClone Pharmaceuticals To Report 2015 Financial Results On March 10, 2016 - [PR Newswire] - FOSTER CITY, Calif., Feb. 22, 2016 /PRNewswire/ -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that it plans to report financial results for the fourth quarter and full year 2015 on Thursday, ...
02/21/16 12:41 PMSciClone Pharmaceuticals, Inc. (SCLN) - SciClone Pharmaceuticals, Inc., a specialty pharmaceutical company, provides therapies for oncology, infectious diseases, and cardiovascular disorders in the People s Republic of China, the United States, and Hong Kong. Its lead product is ZADAXIN, which ...
02/18/16 01:27 PMSciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) Price Target Changes - Risers & Fallers - SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) Price Target ChangesRisers & FallersA number of investment brokers have recently updated their price targets on shares of SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN). According to the latest broker reports outstanding on Wednesday 17th of February, 0 analysts have a rating of “strong ...
02/10/16 12:46 PMGl Partners Capital Management Ltd Recently decreased Its Sciclone Pharmaceuticals Inc Stake - fdanewsalert.com - Gl Partners Capital Management Ltd Recently decreased Its Sciclone Pharmaceuticals Inc Stakefdanewsalert.comGl Partners Capital Management Ltd filed with SEC a SC 13D/A form about Sciclone Pharmaceuticals Inc. The form can be accessed here: 000114420416079709. As reported by Gl Partners Capital Management Ltd, the filler decreased its stake in the stock by ...Blood on the Tracks Hits No. 1 and the Lessons Learned from SciCloneJD Supra (press release)all 5 news articles »
02/10/16 12:46 PMBlood on the Tracks Hits No. 1 and the Lessons Learned from SciClone - This one involved the California based entity SciClone Pharmaceuticals, Inc. (SCLN) which was assessed a penalty of $2.5MM, profit disgorgement of $9.42MM and prejudgment interest of $900K for a total penalty of $12.8MM to settle SEC charges that it ...
02/09/16 12:13 PMManufacturing Sector Top Stocks, Feb. 8 - Intermolecular Inc (IMI)- The company’s shares advanced 8.06 pct. Tyson Foods (TSN)- The company’s stocks rallied 9.47 pct. USG Corp (USG)- The company’s shares advanced 10.1 pct. Sciclone Pharmaceuticals (SCLN)- The company’s shares climbed 8.38 pct.
02/08/16 07:05 AMSciClone Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : February 8, 2016 -
02/06/16 12:38 PMSciClone Pharmaceuticals Inc. (SCLN) Jumps 8.14% on February 05 - Equities.com - SciClone Pharmaceuticals Inc. (SCLN) Jumps 8.14% on February 05Equities.comSciClone Pharmaceuticals Inc. (SCLN) was among the biggest gainers on the Russell 2000 for Friday February 05 as the stock popped 8.14% to $8.77, representing a gain of $0.66 per share. Some 263,814 shares traded hands on 2,260 trades, compared ...Could SciClone Pharmaceuticals, Inc. Recover After Today's Gap Up?Sonoran Weekly Reviewall 4 news articles »
About SciClone Pharmaceuticals

SciClone Pharmaceuticals logoSciClone Pharmaceuticals, Inc. is a pharmaceutical company. The Company's product portfolio of therapies includes oncology, infectious diseases and cardiovascular disorders. The Company operates in two segments: China and the Rest of the World, including its operations in the United States and Hong Kong. The Company's lead product ZADAXIN (thymalfasin) is approved in approximately 30 countries, which is used for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV), and certain cancers according to the local regulatory approvals, and for use as an immune system enhancer. In addition to ZADAXIN, the Company markets approximately seven partnered and in-licensed products in China. The Company's development portfolio includes Angiomax, Neucardin, Loramyc, Cleviprex, RapidFilm, VIBATIV and SGX942. The Company sells ZADAXIN in various international markets through its subsidiary, SciClone Pharmaceuticals International Ltd. (SPIL).

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Drug Manufacturers - Other
  • Sub-Industry: Pharmaceuticals
  • Exchange: NASDAQ
  • Symbol: SCLN
  • CUSIP: 80862K10
Key Metrics:
  • Previous Close: $12.78
  • 50 Day Moving Average: $13.34
  • 200 Day Moving Average: $10.79
  • P/E Ratio: 24.22
  • P/E Growth: 0.00
  • Market Cap: $652.81M
  • Current Quarter EPS Consensus Estimate: $0.33 EPS
Additional Links:
SciClone Pharmaceuticals (NASDAQ:SCLN) Chart for Tuesday, June, 28, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha